摘要
背景:异羟肟酸衍生物的抗肿瘤作用与其作为有效的组蛋白脱乙酰酶抑制剂和其它参与致癌作用的金属酶的性质有很大关系。目的:本研究的目的是:(i)使用实验药物敏感性白血病P388小鼠测定新的外消旋螺环异羟肟酸的抗肿瘤和化学增敏活性,和(ii)确定作为金属螯合和HDAC抑制的结构 - 活性关系代理商。 方法:200-220克重的雄性大鼠进行生化实验。使用22-24g重量的BDF1杂种雄性小鼠进行体内实验。本研究使用脂质过氧化,Fe(II) - 螯合活性,HDAC荧光活性,抗肿瘤和抗转移活性,急性毒性技术。 结果:使用体外活性和体内方法评估水溶性环状异羟肟酸(CHA)的化学增感性质并发现显着的结果。这些化合物具有铁(II)螯合性质,并且轻微抑制脂质过氧化。与由1-甲基哌啶酮(2a-e)制备的CHA相比,由三丙酮胺(1a-e)制备的CHA是更有效的Fe(II)离子螯合剂。组氨酸脱乙酰酶(HDAC)抑制活性,亲脂性和急性毒性受长度氨基酸(大小)(甘氨酸<丙氨酸<缬氨酸<亮氨酸<苯丙氨酸)的影响。带有螺 - N-甲基哌啶环(2a-e)的所有化合物在1250mg / kg剂量时无毒,而带有螺 - 四甲基哌啶环(1a-e)的化合物表现出适度的毒性,其随着增加的亲脂性而增加,但不激发以400mg / kgc.
关键词: HDAC抑制活性,异羟肟酸,化学增敏性,淋巴性白血病,组蛋白脱乙酰化酶,联合化疗。
图形摘要
Current Cancer Drug Targets
Title:Chemosensitizing Activity of Histone Deacetylases Inhibitory Cyclic Hydroxamic Acids for Combination Chemotherapy of Lymphatic Leukemia
Volume: 18 Issue: 4
关键词: HDAC抑制活性,异羟肟酸,化学增敏性,淋巴性白血病,组蛋白脱乙酰化酶,联合化疗。
摘要: Background: Anti-tumor effect of hydroxamic acid derivatives is largely connected with its properties as efficient inhibitors of histone deacetylases, and other metalloenzymes involved in carcinogenesis.
Objective: The work was aimed to (i) determine the anti-tumor and chemosensitizing activity of the novel racemic spirocyclic hydroxamic acids using experimental drug sensitive leukemia P388 of mice, and (ii) determine the structure-activity relationships as metal chelating and HDAC inhibitory agents.
Method: Outbreed male rat of 200-220 g weights were used in biochemical experiments. In vivo experiments were performed using the BDF1 hybrid male mice of 22-24 g weight. Lipid peroxidation, Fe (II) -chelating activity, HDAC fluorescent activity, anti-tumor and anti-metastatic activity, acute toxicity techniques were used in this study.
Results: Chemosensitizing properties of water soluble cyclic hydroxamic acids (CHA) are evaluated using in vitro activities and in vivo methods and found significant results. These compounds possess iron (II) chelating properties, and slightly inhibit lipid peroxidation. CHA prepared from triacetonamine (1a-e) are more effective Fe (II) ions cheaters, as compared to CHA prepared from 1- methylpiperidone (2a-e). The histone deacetylase (HDAC) inhibitory activity, lipophilicity and acute toxicity were influenced by the length amino acids (size) (Glycine < Alanine < Valine < Leucine < Phenylalanine). All compounds bearing spiro-N-methylpiperidine ring (2a-e) are non-toxic up to 1250 mg/kg dose, while compounds bearing spiro-tetramethylpiperidine ring (1a-e) exhibit moderate toxicity which increases with increasing lipophility, but not excite at 400 mg/kg.
Conclusion: It was shown that the use of combination of non-toxic doses of cisplatin (cPt) or cyclophosphamide with CHA in most cases result in the appearance of a considerable anti-tumor effect of cytostatics. The highest chemosensitizing activity with respect to leukemia Р388 is demonstrated by the CHA derivatives of Valine 1c or 2c.
Export Options
About this article
Cite this article as:
Chemosensitizing Activity of Histone Deacetylases Inhibitory Cyclic Hydroxamic Acids for Combination Chemotherapy of Lymphatic Leukemia, Current Cancer Drug Targets 2018; 18 (4) . https://dx.doi.org/10.2174/1568009617666170623104030
DOI https://dx.doi.org/10.2174/1568009617666170623104030 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives
Letters in Organic Chemistry Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets Nutritional Status and Lipid Profile in HIV-Infected Adults
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer
Current Cancer Drug Targets Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function
Mini-Reviews in Medicinal Chemistry Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients
Combinatorial Chemistry & High Throughput Screening Carbon Nanotube Embedded Polymer Composite: Properties and Applications
Current Organic Synthesis Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches
Current Medicinal Chemistry Metabotropic Glutamate Receptor Dependent Cortical Plasticity in Chronic Pain
Current Neuropharmacology Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease
Current Alzheimer Research Intramolecular Cyclisation of β-Aryl-β-Amino Acids in the Design of Novel Heterocyclic Systems with Therapeutic Interest: An Unfailing Source of Diversity
Current Medicinal Chemistry Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Nanoceria: A Novel Cytoprotective Drug Delivery Carrier
Current Nanomedicine In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design